Lyka Labs Limited (LYKALABS.BO)
INR 111.4
(1.6%)
INR 111.4
(1.6%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 29.13 Million INR | 80.62% |
| 2022 | 16.12 Million INR | -97.95% |
| 2021 | 788.27 Million INR | 700.79% |
| 2020 | 98.43 Million INR | 146.76% |
| 2019 | -210.52 Million INR | -70.14% |
| 2018 | -123.73 Million INR | 26.04% |
| 2017 | -167.29 Million INR | -264.74% |
| 2016 | 101.55 Million INR | 21.84% |
| 2015 | 83.34 Million INR | 27.23% |
| 2014 | 65.51 Million INR | 158.25% |
| 2013 | -112.47 Million INR | -205.62% |
| 2012 | 106.49 Million INR | 0.0% |
| 2011 | - INR | -100.0% |
| 2010 | 213.26 Million INR | 29.27% |
| 2009 | 164.97 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 19.5 Million INR | 1297.38% |
| 2023 Q4 | -8.7 Million INR | -121.64% |
| 2023 Q3 | 40.22 Million INR | 384.85% |
| 2023 Q2 | 8.29 Million INR | 200.85% |
| 2023 Q1 | -8.22 Million INR | -195.83% |
| 2023 FY | 29.13 Million INR | 80.62% |
| 2022 FY | 16.12 Million INR | -97.95% |
| 2022 Q4 | -2.78 Million INR | 77.94% |
| 2022 Q3 | -12.6 Million INR | -189.56% |
| 2022 Q2 | 14.07 Million INR | -48.18% |
| 2022 Q1 | 27.15 Million INR | -0.1% |
| 2021 FY | 788.27 Million INR | 700.79% |
| 2021 Q2 | 421.13 Million INR | 51.67% |
| 2021 Q4 | 27.18 Million INR | -74.77% |
| 2021 Q1 | 277.67 Million INR | 563.36% |
| 2021 Q3 | 107.75 Million INR | -74.41% |
| 2020 FY | 98.43 Million INR | 146.76% |
| 2020 Q1 | 22.44 Million INR | 138.67% |
| 2020 Q2 | 17.17 Million INR | -23.49% |
| 2020 Q3 | 38.98 Million INR | 127.05% |
| 2020 Q4 | 41.85 Million INR | 7.37% |
| 2019 Q2 | -22.88 Million INR | 16.16% |
| 2019 Q4 | -58.03 Million INR | -93.05% |
| 2019 Q3 | -30.06 Million INR | -31.35% |
| 2019 FY | -210.52 Million INR | -70.14% |
| 2019 Q1 | -27.3 Million INR | 8.88% |
| 2018 Q1 | -71.18 Million INR | 0.0% |
| 2018 FY | -123.73 Million INR | 26.04% |
| 2018 Q4 | -29.96 Million INR | -212.61% |
| 2018 Q3 | 26.6 Million INR | 141.5% |
| 2018 Q2 | -64.1 Million INR | 9.95% |
| 2017 FY | -167.29 Million INR | -264.74% |
| 2016 Q1 | 1.03 Million INR | -98.32% |
| 2016 Q2 | 53.33 Million INR | 5033.01% |
| 2016 Q3 | 39.25 Million INR | -26.39% |
| 2016 Q4 | 56.52 Million INR | 43.98% |
| 2016 FY | 101.55 Million INR | 21.84% |
| 2015 Q3 | 10.39 Million INR | -75.93% |
| 2015 Q2 | 43.19 Million INR | -46.2% |
| 2015 FY | 83.34 Million INR | 27.23% |
| 2015 Q1 | 80.29 Million INR | 134.0% |
| 2015 Q4 | 61.98 Million INR | 496.15% |
| 2014 Q3 | 136.99 Million INR | 253.8% |
| 2014 Q2 | 38.72 Million INR | 1736.52% |
| 2014 Q1 | -2.36 Million INR | 0.0% |
| 2014 FY | 65.51 Million INR | 158.25% |
| 2014 Q4 | 34.31 Million INR | -74.95% |
| 2013 Q1 | 28.86 Million INR | 153.06% |
| 2013 Q3 | 8.79 Million INR | -70.62% |
| 2013 FY | -112.47 Million INR | -205.62% |
| 2013 Q2 | 29.92 Million INR | 3.66% |
| 2012 Q4 | -54.4 Million INR | 16.19% |
| 2012 Q3 | -64.91 Million INR | -204.37% |
| 2012 Q2 | 62.19 Million INR | 8.97% |
| 2012 FY | 106.49 Million INR | 0.0% |
| 2012 Q1 | 57.07 Million INR | 0.0% |
| 2011 Q3 | -27.49 Million INR | 0.0% |
| 2011 FY | - INR | -100.0% |
| 2010 FY | 213.26 Million INR | 29.27% |
| 2009 FY | 164.97 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 9.28 Million INR | -213.799% |
| Biocon Limited | 50.83 Billion INR | 99.943% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | 99.136% |
| Concord Biotech Limited | 6.26 Billion INR | 99.535% |
| Dishman Carbogen Amcis Limited | -13.9 Million INR | 309.568% |
| FERMENTA BIOTECH LIMITED | 1.06 Billion INR | 97.272% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.27 Million INR | -2183.363% |
| Panacea Biotec Limited | -309.7 Million INR | 109.406% |
| SAMSRITA LABS LIMITED | -1.49 Million INR | 2045.398% |
| Servoteach Industries Limited | -785.00 INR | 3710928.025% |
| SMS Lifesciences India Limited | 359.47 Million INR | 91.896% |
| Supriya Lifescience Limited | 1.57 Billion INR | 98.147% |
| Syngene International Limited | 14.02 Billion INR | 99.792% |
| TAKE Solutions Limited | -213.49 Million INR | 113.645% |
| Titan Biotech Limited | 315.89 Million INR | 90.779% |
| Transgene Biotek Limited | -7.08 Million INR | 510.918% |
| Vanta Bioscience Limited | -31.83 Million INR | 191.494% |